ERBB2 and cancer: Individual ER, PR and HER2 expression scores are provided as well as a Recurrence Score® (RSTM) result generated from a validated algorithm that compares the expression levels of 16 cancer-related genes compared to the expression of 5 housekeeping control reference genes to predict the risk of disease recurrence within 10 years after treatment [11, 12].